Recently, the State Drug Administration approved the marketing of rifusibizumab injection declared by Beijing Shengdi Pharmaceutical Co., Ltd. through a priority review and approval procedure. The drug can be used in combination with a low-fat diet and other lipid-lowering drugs to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above to reduce LDL cholesterol levels. The marketing of this variety provides new treatment options for relevant patients.

Zhitongcaijing · 1d ago
Recently, the State Drug Administration approved the marketing of rifusibizumab injection declared by Beijing Shengdi Pharmaceutical Co., Ltd. through a priority review and approval procedure. The drug can be used in combination with a low-fat diet and other lipid-lowering drugs to treat homozygous familial hypercholesterolemia in adults and adolescents aged 12 and above to reduce LDL cholesterol levels. The marketing of this variety provides new treatment options for relevant patients.